ALKS vs MRK · P/E 14, rev $1.56B vs P/E 33, rev $65.01B
Alkermes Plc (ALKS) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported MRK revenue for 2025-12-31 was $65.01B. Net income was $18.25B. Revenue was up 1.3% from 2024-12-31 to 2025-12-31. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the ALKS and MRK stock pages for the full models.
Not investment advice.